With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.Iovance Biotherapeutics (IOVA 7.54%) is going to finish the week strong on the stock market if its Thursday performance is any indication. Investors boosted the company's share price by almost 8%, following the initiation of coverage by an analyst who's bullish on its future. With that rise, Iovance easily eclipsed the S&P 500 index's 0.2% increase.Vast potential with melanoma drugThe analyst launching his Iovance ...

The biotech is making important breakthroughs, but is that enough? These are exciting times to be an Iovance Biotherapeutics (IOVA) shareholder. The biotech has made encouraging clinical and regulatory progress in the past year. Its most important product is helping it generate strong revenue growth, and although it has been a bit of a wild and volatile ride, its shares have performed much better than the broader market over the trailing 12-month period. It might be worth investing in the stock if the compa ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial. In my previous Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) article, I discussed the company's preparations for the FDA's impending verdict on lifileucel, their tumor-infiltrating lymphocyte ("TIL") therapy for advanced melanoma. I was expecting the ti ...

There's plenty of upside with this stock, but it might take a while to realize. Iovance Biotherapeutics (IOVA 9.30%) is a hot biotech stock for a reason: It's almost certainly going to be growing its top line at a snappy pace over the next few years, and there's no other therapy that's quite like the one it recently started to commercialize. But, like most of the companies in its group, there are a lot of caveats and tidbits of industry knowledge that you'll need to appreciate before you can feel confident ...

Core Viewpoint - Iovance Biotherapeutics has received accelerated approval for its cell therapy treatment, Amtagvi, but investors should be cautious about potential dilution and the company's long path to profitability [1][2][9]. Financial Performance - Iovance generated $31.1 million in sales in its most recent quarter, but reported a net loss of $97.1 million, slightly better than the previous year's loss of $106.5 million [4]. - The company has used $220.7 million in cash for operating activities over the past six months, ending with $235.1 million in cash and $183.9 million in short-term investments [5]. Cash Flow and Dilution Risks - The company faces high dilution risk as it may need to raise funds through equity markets due to insufficient cash flow for operations and expansion [6][8]. - Iovance has a clean balance sheet with total liabilities of $195.8 million against total assets of $964.3 million, indicating a preference for share offerings to raise capital [7]. Market Expansion and Future Outlook - Iovance plans to launch Amtagvi in new markets, including the U.K., Canada, and Australia, which will require additional cash [6][9]. - While the company has growth prospects, the need for cash could lead to significant stock offerings, impacting current investors [9][10].

This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace. It's been a wild roller-coaster ride for Iovance Biotherapeutics (IOVA 0.25%). In February, the stock more than doubled in price, then it fell to a 52-week low in July. The stock has since recovered and at recent prices was up 47% for the year. Can Iovance keep soaring in the years to come, or is its big gain in 2024 more likely to fizzle out? Here's a look at what to expect in the near ...

The biopharma company is proving its recently approved cancer therapy is marketable. After watching its stock fall for weeks on worries of disappointing results, Iovance Biotherapeutics (IOVA 18.64%) has vindicated itself. Shares of the young biopharma company are up 24.2% as of 11:20 a.m. ET today in response to an impressive second-quarter report. This bullish jolt could also mark the beginning of a more prolonged move higher. Iovance's Amtagvi is off to a solid start In simplest terms, caregivers are emb ...

Core Viewpoint - Iovance Biotherapeutics reported better-than-expected earnings and revenue for the second quarter, leading to a significant increase in stock price despite a net loss per share. Financial Performance - Adjusted earnings per share for the second quarter were -34 cents, slightly above the expected -35 cents and an improvement from -47 cents in the same period last year [1] - Revenue for the quarter was reported at $31.11 million, exceeding analysts' expectations of $24.23 million and significantly higher than the $238,000 reported in Q2 2023 [2] Revenue Guidance - The company provided revenue guidance of $53 million to $55 million for Q3, surpassing Wall Street's estimate of $49.04 million [3] - For 2024, Iovance Biotherapeutics expects revenue between $160 million and $165 million, again higher than analysts' estimate of $143.21 million [3] - Revenue expectations for 2025 are projected to be between $450 million and $475 million, exceeding Wall Street's estimate of $403.71 million [4] Stock Market Reaction - Following the earnings report and positive guidance, Iovance Biotherapeutics' stock rose by 18.1% as of Friday afternoon [4]

Iovance Biotherapeutics Inc IOVA stock is trading higher on Friday after the company issued upbeat guidance for 2024 and 2025 and better-than-expected second-quarter earnings. On Thursday, the cancer cell therapy maker Iovance reported second-quarter sales of $31.12 million, surpassing the consensus of $24.6 million. The company reported EPS loss of $(0.34), down from $(0.47) a year ago, beating the consensus of $(0.35). Also Read: Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For ...

Iovance Biotherapeutics, Inc. (IOVA) incurred a loss of 34 cents per share in second-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 37 cents. In the year-ago quarter, the company reported a loss of 47 cents. During the quarter, the company generated total revenues of $31.1 million — entirely from the product sales of its two marketed drugs. The reported sales beat the Zacks Consensus Estimate of $22.6 million. In the year-ago quarter, Iovance recorded total revenues of $0.2 million. Q ...